Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

p53 nuclear accumulation as an early indicator of lethal prostate cancer.

Quinn DI, Stricker PD, Kench JG, Grogan J, Haynes AM, Henshall SM, Grygiel JJ, Delprado W, Turner JJ, Horvath LG, Mahon KL.

Br J Cancer. 2019 Oct;121(7):578-583. doi: 10.1038/s41416-019-0549-8. Epub 2019 Aug 14.

PMID:
31409910
2.

City Cancer Challenge: Changing the Future of Cancer in Urban Populations.

Henshall SM, Villar HV, Doria R, Milner DA Jr.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e121-e125. doi: 10.1200/EDBK_238413. Epub 2019 May 17. Review.

3.

A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.

Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, Boulas J, Vasilaris A, Henshall SM, Stricker PD, Kench JG, Horvath LG.

Ann Oncol. 2017 Aug 1;28(8):1903-1909. doi: 10.1093/annonc/mdx247.

4.

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG.

Br J Cancer. 2015 Apr 14;112(8):1340-8. doi: 10.1038/bjc.2015.74. Epub 2015 Mar 31.

5.

The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.

Susanto JM, Colvin EK, Pinese M, Chang DK, Pajic M, Mawson A, Caldon CE, Musgrove EA, Henshall SM, Sutherland RL, Biankin AV, Scarlett CJ.

Int J Oncol. 2015 May;46(5):2223-30. doi: 10.3892/ijo.2015.2894. Epub 2015 Feb 16.

PMID:
25695794
6.

Expression of phosphorylated-mTOR during the development of prostate cancer.

Sutherland SI, Pe Benito R, Henshall SM, Horvath LG, Kench JG.

Prostate. 2014 Sep;74(12):1231-9. doi: 10.1002/pros.22840. Epub 2014 Jul 7.

PMID:
25043667
7.

Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction.

Scarlett CJ, Colvin EK, Pinese M, Chang DK, Morey AL, Musgrove EA, Pajic M, Apte M, Henshall SM, Sutherland RL, Kench JG, Biankin AV.

PLoS One. 2011;6(10):e26088. doi: 10.1371/journal.pone.0026088. Epub 2011 Oct 14.

8.

High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.

Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG.

BJU Int. 2012 Jun;109(12):1794-800. doi: 10.1111/j.1464-410X.2011.10572.x. Epub 2011 Oct 12.

9.

Pathways of chemotherapy resistance in castration-resistant prostate cancer.

Mahon KL, Henshall SM, Sutherland RL, Horvath LG.

Endocr Relat Cancer. 2011 Jul 4;18(4):R103-23. doi: 10.1530/ERC-10-0343. Print 2011 Aug. Review.

PMID:
21565970
10.

Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer.

Yip PY, Kench JG, Rasiah KK, Benito RP, Lee CS, Stricker PD, Henshall SM, Sutherland RL, Horvath LG.

Prostate. 2011 Nov;71(15):1638-45. doi: 10.1002/pros.21381. Epub 2011 Mar 22.

PMID:
21432866
11.

LMO4 expression in squamous cell carcinoma of the anterior tongue.

Kwong RA, Scarlett CJ, Kalish LH, Cole IE, Kench JG, Sum EY, Musgrove EA, Henshall SM, Lindeman GJ, Biankin AV, Visvader JE, Sutherland RL.

Histopathology. 2011 Feb;58(3):477-80. doi: 10.1111/j.1365-2559.2011.03765.x. No abstract available.

PMID:
21362019
12.

Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers.

Devaney J, Stirzaker C, Qu W, Song JZ, Statham AL, Patterson KI, Horvath LG, Tabor B, Coolen MW, Hulf T, Kench JG, Henshall SM, Pe Benito R, Haynes AM, Mayor R, Peinado MA, Sutherland RL, Clark SJ.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):148-59. doi: 10.1158/1055-9965.EPI-10-0719. Epub 2010 Nov 23.

13.

Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.

Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14.

14.

Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy.

Talantov D, Jatkoe TA, Böhm M, Zhang Y, Ferguson AM, Stricker PD, Kattan MW, Sutherland RL, Kench JG, Wang Y, Henshall SM.

J Urol. 2010 Oct;184(4):1521-8. doi: 10.1016/j.juro.2010.05.084. Epub 2010 Aug 17.

PMID:
20723930
15.

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG.

Cancer Res. 2009 Oct 1;69(19):7696-703. doi: 10.1158/0008-5472.CAN-08-4901. Epub 2009 Sep 22.

16.

Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram.

Thanigasalam R, Rasiah KK, Stricker PD, Haynes AM, Sutherland SI, Sutherland RL, Henshall SM, Horvath LG.

BJU Int. 2010 Mar;105(5):642-7. doi: 10.1111/j.1464-410X.2009.08842.x. Epub 2009 Sep 14.

17.

Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL, Knudsen KE.

Clin Cancer Res. 2009 Sep 1;15(17):5338-49. doi: 10.1158/1078-0432.CCR-08-2865. Epub 2009 Aug 25.

18.

A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes.

Böhm M, Locke WJ, Sutherland RL, Kench JG, Henshall SM.

Oncogene. 2009 Oct 29;28(43):3847-56. doi: 10.1038/onc.2009.243. Epub 2009 Aug 17.

PMID:
19684615
19.

Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.

Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, Henshall SM, Visvader JE, Sutherland RL.

Int J Cancer. 2010 Mar 15;126(6):1445-53. doi: 10.1002/ijc.24826.

20.

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.

Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD.

Cancer Res. 2009 Aug 1;69(15):6131-40. doi: 10.1158/0008-5472.CAN-09-0452. Epub 2009 Jul 28.

21.

Clinically relevant prognostic markers for prostate cancer: the search goes on.

Gelmann EP, Henshall SM.

Ann Intern Med. 2009 May 5;150(9):647-9. No abstract available.

PMID:
19414846
22.

Messina: a novel analysis tool to identify biologically relevant molecules in disease.

Pinese M, Scarlett CJ, Kench JG, Colvin EK, Segara D, Henshall SM, Sutherland RL, Biankin AV.

PLoS One. 2009;4(4):e5337. doi: 10.1371/journal.pone.0005337. Epub 2009 Apr 28.

23.

Margin clearance and outcome in resected pancreatic cancer.

Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RW, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG, Biankin AV.

J Clin Oncol. 2009 Jun 10;27(17):2855-62. doi: 10.1200/JCO.2008.20.5104. Epub 2009 Apr 27.

PMID:
19398572
24.

Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.

Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ, Chang DK, Morey AL, Lee CS, Pinese M, Kuo SC, Susanto JM, Cosman PH, Lindeman GJ, Visvader JE, Nguyen TV, Merrett ND, Warusavitarne J, Musgrove EA, Henshall SM, Sutherland RL; NSW Pancreatic Cancer Network.

Gastroenterology. 2009 Aug;137(2):558-68, 568.e1-11. doi: 10.1053/j.gastro.2009.04.009. Epub 2009 Apr 16.

PMID:
19376121
25.

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.

Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES.

Oncogene. 2009 Apr 16;28(15):1812-20. doi: 10.1038/onc.2009.13. Epub 2009 Mar 16.

26.

HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer.

Rasiah KK, Gardiner-Garden M, Padilla EJ, Möller G, Kench JG, Alles MC, Eggleton SA, Stricker PD, Adamski J, Sutherland RL, Henshall SM, Hayes VM.

Mol Cell Endocrinol. 2009 Mar 25;301(1-2):89-96. doi: 10.1016/j.mce.2008.11.021. Epub 2008 Nov 28.

PMID:
19100308
27.

BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.

Millar EK, Anderson LR, McNeil CM, O'Toole SA, Pinese M, Crea P, Morey AL, Biankin AV, Henshall SM, Musgrove EA, Sutherland RL, Butt AJ.

Br J Cancer. 2009 Jan 13;100(1):123-33. doi: 10.1038/sj.bjc.6604809. Epub 2008 Dec 9.

28.

Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse.

Sakko AJ, Butler MS, Byers S, Reinboth BJ, Stahl J, Kench JG, Horvath LG, Sutherland RL, Stricker PD, Henshall SM, Marshall VR, Tilley WD, Horsfall DJ, Ricciardelli C.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2488-97. doi: 10.1158/1055-9965.EPI-08-0204.

29.

Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.

Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES.

Cancer Res. 2008 Jul 15;68(14):5628-38. doi: 10.1158/0008-5472.CAN-07-3170.

30.

Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.

Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD, Horvath LG.

Prostate. 2008 Sep 15;68(13):1421-9. doi: 10.1002/pros.20809.

PMID:
18615486
31.

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams ED, Scurr L, Defazio A, Quinn DI, Watts CK, Hacker NF, Henshall SM, Sutherland RL.

Br J Cancer. 2008 Mar 25;98(6):1085-93. doi: 10.1038/sj.bjc.6604281. Epub 2008 Mar 18. Erratum in: Br J Cancer. 2008 Jun 3;98(11):1880. Murali, Rajmohan [added].

32.

Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma.

Murphy NC, Scarlett CJ, Kench JG, Sum EY, Segara D, Colvin EK, Susanto J, Cosman PH, Lee CS, Musgrove EA, Sutherland RL, Lindeman GJ, Henshall SM, Visvader JE, Biankin AV.

Br J Cancer. 2008 Feb 12;98(3):537-41. doi: 10.1038/sj.bjc.6604177. Epub 2008 Jan 29.

33.

Common activation of canonical Wnt signaling in pancreatic adenocarcinoma.

Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJ, Deramaudt T, Segara D, Dawson AC, Kench JG, Henshall SM, Sutherland RL, Dlugosz A, Rustgi AK, Hebrok M.

PLoS One. 2007 Nov 7;2(11):e1155.

34.

Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.

Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, Saunders DN, Grygiel JJ, Sutherland RL, Henshall SM.

Prostate. 2007 Jul 1;67(10):1081-90.

PMID:
17476687
35.

c-Myc overexpression and endocrine resistance in breast cancer.

McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, Murphy NC, Millar EK, Crea P, Kench JG, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ, Henshall SM, Musgrove EA, Sutherland RL.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):147-55. Epub 2006 Oct 18.

PMID:
17052904
36.

Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.

Skalicky DA, Kench JG, Segara D, Coleman MJ, Sutherland RL, Henshall SM, Musgrove EA, Biankin AV.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1941-7.

37.

Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.

Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL.

J Natl Cancer Inst. 2006 Oct 4;98(19):1420-4.

PMID:
17018789
38.

Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis.

Rasiah KK, Kench JG, Gardiner-Garden M, Biankin AV, Golovsky D, Brenner PC, Kooner R, O'neill GF, Turner JJ, Delprado W, Lee CS, Brown DA, Breit SN, Grygiel JJ, Horvath LG, Stricker PD, Sutherland RL, Henshall SM.

Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):711-6.

39.

A distinct molecular profile associated with mucinous epithelial ovarian cancer.

Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM.

Br J Cancer. 2006 Mar 27;94(6):904-13.

40.

EphB4 expression and biological significance in prostate cancer.

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS.

Cancer Res. 2005 Jun 1;65(11):4623-32.

41.

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.

Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ.

Cancer Res. 2005 May 15;65(10):4031-40. Erratum in: Cancer Res. 2005 Sep 1;65(17):8057.

42.

Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia.

Segara D, Biankin AV, Kench JG, Langusch CC, Dawson AC, Skalicky DA, Gotley DC, Coleman MJ, Sutherland RL, Henshall SM.

Clin Cancer Res. 2005 May 1;11(9):3587-96.

43.

Molecular markers of prostate cancer outcome.

Quinn DI, Henshall SM, Sutherland RL.

Eur J Cancer. 2005 Apr;41(6):858-87. Review.

PMID:
15808955
44.

The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome.

Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D, Kuffner T, Pankhurst GJ, Johnen H, Russell PJ, Barret W, Stricker PD, Grygiel JJ, Kench JG, Henshall SM, Sutherland RL, Breit SN.

Cancer Res. 2005 Mar 15;65(6):2330-6.

45.

Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.

Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Int J Cancer. 2005 Jan 20;113(3):415-22.

46.

Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence.

Biankin AV, Kench JG, Biankin SA, Lee CS, Morey AL, Dijkman FP, Coleman MJ, Sutherland RL, Henshall SM.

Am J Surg Pathol. 2004 Sep;28(9):1184-92.

PMID:
15316318
47.

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA.

Mol Cancer Ther. 2004 Aug;3(8):921-32.

48.

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.

Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM.

Clin Cancer Res. 2004 Aug 1;10(15):5168-77.

49.

Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.

Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM.

Clin Cancer Res. 2004 Jul 1;10(13):4427-36.

50.

Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression.

Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Prostate. 2004 May 15;59(3):234-42.

PMID:
15042598

Supplemental Content

Loading ...
Support Center